170 related articles for article (PubMed ID: 26302952)
1. Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis.
Lo Y; Shen LJ; Chen WH; Dong YH; Wu FL
J Formos Med Assoc; 2016 Sep; 115(9):744-51. PubMed ID: 26302952
[TBL] [Abstract][Full Text] [Related]
2. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Szabatura AH; Cirrone F; Harris C; McDonnell AM; Feng Y; Voit D; Neuberg D; Butrynski J; Fisher DC
J Oncol Pharm Pract; 2015 Jun; 21(3):188-93. PubMed ID: 24664476
[TBL] [Abstract][Full Text] [Related]
3. Evaluating risk factors for the development of ifosfamide encephalopathy.
David KA; Picus J
Am J Clin Oncol; 2005 Jun; 28(3):277-80. PubMed ID: 15923801
[TBL] [Abstract][Full Text] [Related]
4. Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.
Sweiss KI; Beri R; Shord SS
Drug Saf; 2008; 31(11):989-96. PubMed ID: 18840018
[TBL] [Abstract][Full Text] [Related]
5. [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
Stern N; Sakji I; Defachelles AS; Lervat C; Ryckewaert T; Marliot G; Peugniez C; Deplanque D; Penel N
Bull Cancer; 2017 Mar; 104(3):208-212. PubMed ID: 27986268
[TBL] [Abstract][Full Text] [Related]
6. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide related encephalopathy: the need for a timely EEG evaluation.
Feyissa AM; Tummala S
J Neurol Sci; 2014 Jan; 336(1-2):109-12. PubMed ID: 24209900
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®).
Chambord J; Henny F; Salleron J; Hombourger B; Lider P; Vigneron J; Demore B; Vallance C; Rios M
J Clin Pharm Ther; 2019 Jun; 44(3):372-380. PubMed ID: 30830971
[TBL] [Abstract][Full Text] [Related]
9. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
10. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
[TBL] [Abstract][Full Text] [Related]
11. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide-induced encephalopathy and movement disorder.
Ames B; Lewis LD; Chaffee S; Kim J; Morse R
Pediatr Blood Cancer; 2010 Apr; 54(4):624-6. PubMed ID: 19953647
[TBL] [Abstract][Full Text] [Related]
13. Incidence and severity of ifosfamide-induced encephalopathy.
Rieger C; Fiegl M; Tischer J; Ostermann H; Schiel X
Anticancer Drugs; 2004 Apr; 15(4):347-50. PubMed ID: 15057138
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case.
Müngen E; Yaman Bajin İ; Öz S; Günbey C; Anlar B; Aydin B
J Pediatr Hematol Oncol; 2022 Oct; 44(7):402-404. PubMed ID: 35536996
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
Cherry MA; Bhardwaj H; Hopps S; Srour S; Pant S
J Oncol Pharm Pract; 2013 Sep; 19(3):261-4. PubMed ID: 23135805
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
Tajino T; Kikuchi S; Yamada H; Takeda A; Konno S
J Orthop Sci; 2010 Jan; 15(1):104-11. PubMed ID: 20151259
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
Brunello A; Basso U; Rossi E; Stefani M; Ghiotto C; Marino D; Crivellari G; Monfardini S
Drugs Aging; 2007; 24(11):967-73. PubMed ID: 17953463
[TBL] [Abstract][Full Text] [Related]
18. Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?
Abahssain H; Moukafih B; Essangri H; Mrabti H; Meddah B; Guessous F; Fadhil FZ; Souadka A; Errihani H
J Oncol Pharm Pract; 2021 Jan; 27(1):143-149. PubMed ID: 33153383
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ifosfamide encephalopathy with intravenous thiamin.
Buesa JM; García-Teijido P; Losa R; Fra J
Clin Cancer Res; 2003 Oct; 9(12):4636-7. PubMed ID: 14555540
[No Abstract] [Full Text] [Related]
20. Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population.
Hillaire-Buys D; Mousset M; Allouchery M; Azzouz B; Babin M; Bellet F; Béné J; Default A; Durrieu G; Géniaux H; Grandvuillemin A; Gras-Champel V; Jantzem H; Lambert A; Lepelley M; Massy N; Petitpain N; Rocher F; Sanchez-Pena P; Sassier M; Simon C; Triquet L; Valnet-Rabier MB; Veyrac G; Faillie JL; Zenut MC
Therapie; 2020; 75(5):471-480. PubMed ID: 31732241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
